ORIONISBIO
Live / Applied — Second extension granted (statement of use) (as of 24 Oct 2025)
What this means for you
Not registered yet, but its 02 Jan 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98338329
- Mark type
- Stylized text
- Filed
- 02 Jan 2024
- Published for opposition
- 03 Sept 2024
- Attorney of record
- Rachelle A. Dubow, Esq.
Goods and services
- Class 001 — Chemicals: Diagnostic, biological and chemical reagents for scientific and research use; Pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; Active chemical or biological ingredients for use in the manufacture of pharmaceuticals for treating cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases; Cytokines, namely, reagents for scientific and research use
- Class 005 — Pharmaceuticals: Pharmaceutical products, serums and preparations for the treatment of cancer, auto immune disorders, metabolic disorders, neurological disorders, neuromuscular disorder; Pharmaceutical preparations, namely, cytokine inhibitory drugs; Therapeutic pharmaceutical and diagnostic preparations, namely, antibodies, cytokines, antigens, enzymes, immunoconjugates for treatment of cancer, immunological conditions, metabolic disorders; Biochemical and small molecule preparations for medical purposes for use in the treatment of cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases
- Class 042 — Scientific and technological services: Development of new technology for others in the field of biotechnology; Scientific research and laboratory research services in the medical, bacteriological and biotechnical fields; Biotechnical research; Technical consultation and research in the field of biotechnological research; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Research and development of pharmaceuticals for others; Scientific and medical research in the fields of oncology, immunology and immune-oncology, inflammation, immune-mediated diseases, protein homeostasis, epigenetics and protein metabolism
Owner
- Orionis Biosciences Inc., Waltham, MA, US
- Orionis Biosciences Inc., Waltham, MA, US
Prosecution history
- 27 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Oct 2025 — SOU EXTENSION 2 GRANTED
- 24 Oct 2025 — SOU EXTENSION 2 FILED
- 24 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Apr 2025 — SOU EXTENSION 1 GRANTED
- 11 Apr 2025 — SOU EXTENSION 1 FILED
- 10 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 29 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Sept 2024 — PUBLISHED FOR OPPOSITION
- 14 Aug 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 30 Jul 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 Jul 2024 — EXAMINER'S AMENDMENT ENTERED
- 30 Jul 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED